🆕‘‘Assessing safety and efficacy of TNFi treatment in late onset #ankylosingspondylitis : a TURKBIO registry study’’ @SciReports 👇 https://t.co/puL8KQaLfO
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026@RheumNow
IL-6 blockade has transformed the treatment of GCA. But is targeting a single cytokine enough? Persistent T-cell infiltrates within the vessel wall, relapses after tocilizumab withdrawal and the role of IFNγ suggest a more complex disease biology. #EULAR2026
My sincere thanks to the organizing committee of the “3rd Manisa Rheumatology Days” for the thoughtfully prepared program and excellent organization. It was a pleasure to be part of such a valuable and inspiring meeting 🙏🏼🌿 @sadouslu@OzgurAkgulMD@Nurullah_Akkoc
Inflammatory myopathies are typically associated with a myositis-specific autoantibody that determines the diagnosis and prognosis. Myositis subgroups have distinct pathomechanisms that now allow for targeted therapies.
Learn more in the Review Article “Inflammatory Myopathies” by Yves Allenbach, MD, PhD, and Olivier Benveniste, MD, PhD: https://t.co/ZeCKdNe87v
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
➠ Read the Full Guideline: https://t.co/jNwvKWbFpE
#RheumX#RheumTwitter#Rheum@RheumNow
NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow#ACR25 Abstr#1024